Literature DB >> 23419824

The burden of liver disease in Europe: a review of available epidemiological data.

Martin Blachier1, Henri Leleu, Markus Peck-Radosavljevic, Dominique-Charles Valla, Françoise Roudot-Thoraval.   

Abstract

To survey the burden of liver disease in Europe and its causes 260 epidemiological studies published in the last five years were reviewed. The incidence and prevalence of cirrhosis and primary liver cancer are key to understand the burden of liver disease. They represent the end-stage of liver pathology and thus are indicative of the associated mortality. About 0.1% of Hungarian males will die of cirrhosis every year compared with 0.001% of Greek females. WHO estimate that liver cancer is responsible for around 47,000 deaths per year in the EU. Harmful alcohol consumption, viral hepatitis B and C and metabolic syndromes related to overweight and obesity are the leading causes of cirrhosis and primary liver cancer in Europe. Chronic hepatitis B affects 0.5-0.7% of the European population. In the last decade the prevalence of chronic hepatitis C was 0.13-3.26%. It is of great concern that about 90% of people in Europe infected by viral hepatitis are unaware of their status. Available data suggest the prevalence rate of NAFLD is 2-44% in the general European population (including obese children) and 42.6-69.5% in people with type 2 diabetes. Each of these four major causes of liver disease is amenable to prevention and treatment, reducing the burden of liver disease in Europe and saving lives. Further surveys are urgently needed to implement cost-effective prevention programmes and novel treatments to tackle this problem.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23419824     DOI: 10.1016/j.jhep.2012.12.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  363 in total

1.  Epidemiology of Liver Cirrhosis.

Authors:  Cristina Stasi; Caterina Silvestri; Fabio Voller; Francesco Cipriani
Journal:  J Clin Exp Hepatol       Date:  2015-06-14

Review 2.  Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review.

Authors:  Anam Khan; Aylin Tansel; Donna L White; Waleed Tallat Kayani; Shah Bano; Jan Lindsay; Hashem B El-Serag; Fasiha Kanwal
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-06       Impact factor: 11.382

Review 3.  Osteoporosis across chronic liver disease.

Authors:  M Guarino; I Loperto; S Camera; V Cossiga; C Di Somma; A Colao; N Caporaso; F Morisco
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

4.  Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment.

Authors:  Brian D Jamieson; Sabrina Ciric; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 5.  Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors:  E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal:  Pharmacogenomics J       Date:  2015-04-28       Impact factor: 3.550

Review 6.  Recent updates on phthalate exposure and human health: a special focus on liver toxicity and stem cell regeneration.

Authors:  Sarva Mangala Praveena; Seoh Wei Teh; Ranjith Kumar Rajendran; Narayanan Kannan; Chu-Ching Lin; Rozaini Abdullah; Suresh Kumar
Journal:  Environ Sci Pollut Res Int       Date:  2018-03-15       Impact factor: 4.223

Review 7.  Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology.

Authors:  Guy Bower; Tania Toma; Leanne Harling; Long R Jiao; Evangelos Efthimiou; Ara Darzi; Thanos Athanasiou; Hutan Ashrafian
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

8.  Factors affecting inadequate response to HBV vaccine in hemodialysis patients: northeast anatolia survey with six hemodialysis centers.

Authors:  Halil İbrahim Erdoğdu; Eray Atalay; Gül Gürsoy; Başol Canbakan; Serkan Aktürk; Canan Yazıcı; Orhan Yücel; Sinan Mersin; Sengül Üçer; Özgür Merhametsiz; Can Öner; Merve Erat
Journal:  Clin Exp Nephrol       Date:  2018-11-28       Impact factor: 2.801

9.  Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.

Authors:  Lynda Aoudjehane; Pierre-Yves Boelle; Grégoire Bisch; Rolland Delelo; François Paye; Olivier Scatton; Chantal Housset; Jérôme Becquart; Yvon Calmus; Filomena Conti
Journal:  Lab Invest       Date:  2016-03-07       Impact factor: 5.662

10.  Quantification of liver proton-density fat fraction in 7.1T preclinical MR systems: Impact of the fitting technique.

Authors:  Christoph Mahlke; Diego Hernando; Christina Jahn; Antonio Cigliano; Till Ittermann; Anne Mössler; Marie-Luise Kromrey; Grazyna Domaska; Scott B Reeder; Jens-Peter Kühn
Journal:  J Magn Reson Imaging       Date:  2016-05-19       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.